Tyra Biosciences (TYRA)
Tyra Biosciences on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
9.5M
Short interest
settlement 2026-10-15
15.3
Days to cover
+6.5 days vs prior
81.1%
Short share of volume
2026-11-02
2,652
Fails to deliver
settlement 2026-09-25
Wed 4 Nov
Next earnings
estimated date
$20K
Insider flow, 90 days
1 buys, 0 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in TYRA is 9,495,754 shares, down 381,210 shares over the last month. Over the last 48 readings it ranged from 1,756,303 shares (31 October 2024) to 11,924,900 shares (30 June 2026). At the reported average volume of 620K shares a day that is 15.3 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/tyra" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 9,495,754 | +0.9% | 619,597 | 15.33 |
| 2026-09-30 | 9,414,018 | -4.7% | 1,066,287 | 8.83 |
| 2026-09-15 | 9,876,964 | +4.6% | 1,737,646 | 5.68 |
| 2026-08-31 | 9,440,216 | -2.6% | 347,850 | 27.14 |
| 2026-08-14 | 9,689,392 | +4.8% | 766,180 | 12.65 |
| 2026-07-31 | 9,246,935 | -6.9% | 518,736 | 17.83 |
| 2026-07-15 | 9,930,770 | -16.7% | 640,837 | 15.50 |
| 2026-06-30 | 11,924,900 | +20.9% | 1,273,015 | 9.37 |
| 2026-06-15 | 9,866,801 | +6.3% | 1,072,493 | 9.20 |
| 2026-05-29 | 9,281,430 | +15.1% | 707,583 | 13.12 |
| 2026-05-15 | 8,065,431 | +4.6% | 637,653 | 12.65 |
| 2026-04-30 | 7,708,671 | -0.0% | 1,153,312 | 6.68 |
| 2026-04-15 | 7,709,241 | -6.7% | 1,013,045 | 7.61 |
| 2026-03-31 | 8,264,887 | +20.6% | 1,041,198 | 7.94 |
| 2026-03-13 | 6,853,153 | +20.9% | 1,656,105 | 4.14 |
| 2026-02-27 | 5,667,913 | +10.2% | 754,760 | 7.51 |
| 2026-02-13 | 5,144,732 | +2.6% | 752,172 | 6.84 |
| 2026-01-30 | 5,013,172 | -1.2% | 766,499 | 6.54 |
| 2026-01-15 | 5,073,265 | -12.4% | 609,223 | 8.33 |
| 2025-12-31 | 5,791,320 | +36.6% | 543,765 | 10.65 |
| 2025-12-15 | 4,238,532 | +2.2% | 466,449 | 9.09 |
| 2025-11-28 | 4,146,608 | -5.2% | 720,993 | 5.75 |
| 2025-11-14 | 4,375,041 | -7.0% | 237,625 | 18.41 |
| 2025-10-31 | 4,706,779 | -18.6% | 285,072 | 16.51 |
| 2025-10-15 | 5,782,614 | -2.3% | 174,202 | 33.19 |
| 2025-09-30 | 5,915,988 | -0.6% | 178,901 | 33.07 |
| 2025-09-15 | 5,952,493 | +0.6% | 226,894 | 26.23 |
| 2025-08-29 | 5,919,802 | +3.0% | 254,265 | 23.28 |
| 2025-08-15 | 5,745,735 | -3.6% | 174,709 | 32.89 |
| 2025-07-31 | 5,960,103 | -1.3% | 205,982 | 28.94 |
| 2025-07-15 | 6,038,364 | +8.6% | 320,558 | 18.84 |
| 2025-06-30 | 5,560,975 | +5.7% | 390,249 | 14.25 |
| 2025-06-13 | 5,260,707 | +5.7% | 466,531 | 11.28 |
| 2025-05-30 | 4,976,683 | -2.5% | 253,679 | 19.62 |
| 2025-05-15 | 5,101,753 | +17.2% | 334,449 | 15.25 |
| 2025-04-30 | 4,354,579 | +10.6% | 236,396 | 18.42 |
| 2025-04-15 | 3,935,750 | +5.0% | 450,602 | 8.73 |
| 2025-03-31 | 3,747,503 | -4.3% | 221,601 | 16.91 |
| 2025-03-14 | 3,915,958 | -3.9% | 461,062 | 8.49 |
| 2025-02-28 | 4,076,761 | +10.7% | 201,216 | 20.26 |
| 2025-02-14 | 3,683,138 | +30.6% | 296,058 | 12.44 |
| 2025-01-31 | 2,819,264 | +1.7% | 201,774 | 13.97 |
| 2025-01-15 | 2,772,076 | +9.3% | 319,986 | 8.66 |
| 2024-12-31 | 2,536,656 | +0.1% | 198,495 | 12.78 |
| 2024-12-13 | 2,534,638 | +26.1% | 218,583 | 11.60 |
| 2024-11-29 | 2,009,811 | +7.5% | 196,137 | 10.25 |
| 2024-11-15 | 1,870,520 | +6.5% | 360,096 | 5.19 |
| 2024-10-31 | 1,756,303 | -20.1% | 771,266 | 2.28 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of TYRA volume is 81.1%, up 17.5 points over the last five sessions. Over the last 30 readings it ranged from 47.3% (22 October 2026) to 90.9% (30 September 2026). The latest reading is 6.4 points above the 30-session average of 74.7%, on 203K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 165K | 203K | 81.1% | 0 |
| 2026-10-30 | 127K | 210K | 60.3% | 0 |
| 2026-10-29 | 144K | 267K | 53.8% | 0 |
| 2026-10-28 | 66K | 87K | 76.0% | 0 |
| 2026-10-27 | 119K | 153K | 77.8% | 0 |
| 2026-10-26 | 147K | 231K | 63.6% | 0 |
| 2026-10-23 | 146K | 175K | 83.6% | 0 |
| 2026-10-22 | 178K | 375K | 47.3% | 0 |
| 2026-10-21 | 212K | 253K | 83.8% | 11,671 |
| 2026-10-20 | 256K | 293K | 87.3% | 0 |
| 2026-10-19 | 295K | 360K | 82.0% | 0 |
| 2026-10-16 | 141K | 159K | 88.6% | 0 |
| 2026-10-15 | 119K | 152K | 78.4% | 0 |
| 2026-10-14 | 90K | 128K | 70.4% | 0 |
| 2026-10-13 | 87K | 117K | 74.8% | 0 |
| 2026-10-12 | 57K | 98K | 57.7% | 0 |
| 2026-10-09 | 191K | 259K | 74.0% | 18,878 |
| 2026-10-08 | 146K | 179K | 81.7% | 0 |
| 2026-10-07 | 132K | 161K | 81.8% | 0 |
| 2026-10-06 | 236K | 304K | 77.6% | 0 |
| 2026-10-05 | 156K | 219K | 71.3% | 0 |
| 2026-10-02 | 234K | 376K | 62.3% | 0 |
| 2026-10-01 | 313K | 445K | 70.2% | 0 |
| 2026-09-30 | 378K | 416K | 90.9% | 0 |
| 2026-09-29 | 156K | 196K | 80.0% | 0 |
| 2026-09-28 | 314K | 372K | 84.4% | 0 |
| 2026-09-25 | 228K | 317K | 72.1% | 0 |
| 2026-09-24 | 241K | 455K | 52.9% | 6,384 |
| 2026-09-23 | 435K | 500K | 87.0% | 8,509 |
| 2026-09-22 | 237K | 265K | 89.5% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 25 September 2026, the fails-to-deliver balance in TYRA is 2,652 shares, down 14,892 shares over the last settlement date. Over the last 30 readings it ranged from 5 shares (16 July 2026) to 55,459 shares (1 July 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-25 | 2,652 | $22.41 | $59K |
| 2026-09-16 | 17,544 | $25.43 | $446K |
| 2026-09-15 | 5,842 | $25.07 | $146K |
| 2026-09-14 | 8,956 | $22.03 | $197K |
| 2026-09-11 | 15,523 | $23.54 | $365K |
| 2026-09-10 | 17,567 | $22.01 | $387K |
| 2026-09-02 | 277 | $25.30 | $7K |
| 2026-08-28 | 5,599 | $26.13 | $146K |
| 2026-08-27 | 3,765 | $26.22 | $99K |
| 2026-08-25 | 313 | $26.09 | $8K |
| 2026-08-17 | 13,404 | $25.29 | $339K |
| 2026-08-14 | 25,757 | $25.02 | $644K |
| 2026-08-12 | 2,001 | $25.18 | $50K |
| 2026-08-05 | 2,087 | $32.53 | $68K |
| 2026-08-03 | 30 | $31.88 | $956 |
| 2026-07-31 | 536 | $33.06 | $18K |
| 2026-07-30 | 4,168 | $31.11 | $130K |
| 2026-07-28 | 12,918 | $31.06 | $401K |
| 2026-07-27 | 461 | $30.63 | $14K |
| 2026-07-16 | 5 | $32.38 | $162 |
| 2026-07-15 | 1,535 | $32.88 | $50K |
| 2026-07-09 | 1,004 | $32.57 | $33K |
| 2026-07-02 | 49,845 | $29.41 | $1.5M |
| 2026-07-01 | 55,459 | $31.94 | $1.8M |
| 2026-06-30 | 30,552 | $32.11 | $981K |
| 2026-06-29 | 32,703 | $31.88 | $1.0M |
| 2026-06-26 | 28,839 | $30.94 | $892K |
| 2026-06-25 | 1,450 | $30.37 | $44K |
| 2026-06-24 | 587 | $30.06 | $18K |
| 2026-06-23 | 1,205 | $30.14 | $36K |
Insider trades
SEC Form 4, newest first. JSONInsiders at TYRA reported 1 open-market buy worth $20K in the last 90 days and no open-market sells. Latest filing: Fuhrman Alan (Chief Financial Officer) on 2026-09-15.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-15 | Fuhrman Alan | Chief Financial Officer | Grant | 951 | $9.13 | $9K | 37K |
| 2026-09-15 | Rueb Yuliya | Vice President, Finance (PAO) | Grant | 3K | $9.13 | $27K | 11K |
| 2026-09-15 | Harris Todd | President and CEO | Grant | 864 | $9.13 | $8K | 1.4M |
| 2026-09-09 | Verjee Rehan | Director | Buy | 972 | $20.58 | $20K | 972 |
| 2026-05-05 | Warner Douglas J | Chief Medical Officer | Grant | 25K | $0.00 | $0 | 25K |
| 2026-05-05 | Rueb Yuliya | Vice President, Finance (PAO) | Grant | 8K | $0.00 | $0 | 43K |
| 2026-05-05 | Harris Todd | President and CEO | Grant | 79K | $0.00 | $0 | 1.4M |
| 2026-05-05 | Fuhrman Alan | Chief Financial Officer | Grant | 20K | $0.00 | $0 | 36K |
| 2026-05-05 | Ashar Bhavesh | Chief Operating Officer | Grant | 15K | $0.00 | $0 | 15K |
| 2026-03-26 | KAPLAN GILLA | Director | Returned to company | 53K | $37.75 | $2.0M | 28K |
| 2026-03-26 | KAPLAN GILLA | Director | Exercise or conversion | 53K | $2.25 | $120K | 81K |
| 2026-03-25 | KAPLAN GILLA | Director | Sell | 14K | $36.97 | $529K | 28K |
| 2026-03-25 | KAPLAN GILLA | Director | Exercise or conversion | 14K | $2.25 | $32K | 43K |
| 2026-03-13 | Harris Todd | President and CEO | Grant | 1K | $9.13 | $13K | 1.4M |
| 2026-03-13 | Fuhrman Alan | Chief Financial Officer | Grant | 1K | $9.13 | $13K | 16K |
| 2026-02-12 | Bensen Daniel | Chief Discovery Officer | Sell | 6K | $33.37 | $196K | 147K |
| 2026-02-12 | Bensen Daniel | Chief Discovery Officer | Sell | 2K | $31.50 | $67K | 153K |
| 2026-01-12 | Bensen Daniel | Chief Discovery Officer | Sell | 1K | $29.08 | $30K | 155K |
| 2026-01-12 | Bensen Daniel | Chief Discovery Officer | Sell | 7K | $28.44 | $199K | 156K |
| 2025-12-19 | MORE ROBERT J | Director | Sell | 10K | $25.00 | $250K | 3.8M |
| 2025-12-12 | Bensen Daniel | Chief Discovery Officer | Sell | 8K | $22.64 | $181K | 163K |
| 2025-11-21 | MORE ROBERT J | Director | Sell | 247K | $20.25 | $5.0M | 3.8M |
| 2025-11-19 | Bensen Daniel | Chief Operating Officer | Sell | 50K | $16.32 | $815K | 171K |
| 2025-11-18 | Bensen Daniel | Chief Operating Officer | Sell | 76K | $16.07 | $1.2M | 221K |
| 2025-11-17 | Bensen Daniel | Chief Operating Officer | Sell | 2K | $17.07 | $26K | 297K |
| 2025-11-17 | Bensen Daniel | Chief Operating Officer | Sell | 19K | $16.11 | $299K | 298K |
| 2025-11-14 | Bensen Daniel | Chief Operating Officer | Sell | 110K | $16.02 | $1.8M | 317K |
| 2025-11-13 | Bensen Daniel | Chief Operating Officer | Sell | 1K | $16.00 | $18K | 427K |
| 2025-09-15 | Fuhrman Alan | Chief Financial Officer | Grant | 701 | $9.13 | $6K | 15K |
| 2025-06-18 | KAPLAN GILLA | Director | Sell | 10K | $9.78 | $94K | 28K |
| 2025-06-17 | KAPLAN GILLA | Director | Sell | 10 | $10.35 | $104 | 38K |
| 2025-06-16 | RA CAPITAL MANAGEMENT, L.P. | Director, 10% owner | Buy | 12K | $10.13 | $120K | 10.3M |
| 2025-06-16 | KAPLAN GILLA | Director | Sell | 7K | $10.38 | $71K | 38K |
| 2025-06-13 | RA CAPITAL MANAGEMENT, L.P. | Director, 10% owner | Buy | 120K | $10.20 | $1.2M | 10.2M |
| 2025-06-13 | KAPLAN GILLA | Director | Sell | 15K | $10.31 | $155K | 45K |
| 2025-06-12 | RA CAPITAL MANAGEMENT, L.P. | Director, 10% owner | Buy | 31K | $10.20 | $319K | 10.1M |
| 2025-06-12 | KAPLAN GILLA | Director | Sell | 30K | $10.31 | $309K | 60K |
| 2025-06-09 | RA Capital Healthcare Fund LP | Director,TenPercentOwner | Buy | 187K | $10.19 | $1.9M | 10.1M |
| 2025-06-05 | Kolchinsky Peter | Director,TenPercentOwner | Buy | 213K | $10.04 | $2.1M | 9.9M |
| 2025-06-04 | Kolchinsky Peter | Director,TenPercentOwner | Buy | 998K | $9.63 | $9.6M | 9.7M |
| 2025-03-14 | Fuhrman Alan | Chief Financial Officer | Grant | 1K | $9.78 | $12K | 14K |
| 2025-03-14 | Harris Todd | President and CEO | Grant | 1K | $9.78 | $12K | 1.4M |
| 2025-02-05 | Kjellson Nina S | Director | Sell | 4K | $13.76 | $48K | 444K |
| 2025-02-05 | Kjellson Nina S | Director | Sell | 2K | $13.76 | $26K | 3.7M |
| 2025-01-23 | Kjellson Nina S | Director | Sell | 5K | $16.26 | $78K | 3.7M |
| 2025-01-21 | Kjellson Nina S | Director | Sell | 4K | $16.36 | $65K | 3.7M |
| 2025-01-17 | Kjellson Nina S | Director | Sell | 13K | $16.40 | $210K | 3.7M |
| 2025-01-17 | Kjellson Nina S | Director | Sell | 461 | $16.40 | $8K | 447K |
| 2025-01-16 | Kjellson Nina S | Director | Sell | 835 | $16.29 | $14K | 448K |
| 2025-01-16 | Kjellson Nina S | Director | Sell | 7K | $16.29 | $113K | 3.7M |
| 2024-11-25 | Kjellson Nina S | Director | Sell | 566 | $16.84 | $10K | 449K |
| 2024-11-25 | Kjellson Nina S | Director | Sell | 5K | $16.84 | $79K | 3.7M |
| 2024-11-08 | RA Capital Healthcare Fund LP | Director,TenPercentOwner | Buy | 1.2M | $16.25 | $19.8M | 8.7M |
| 2024-11-07 | Kjellson Nina S | Director | Sell | 20K | $17.32 | $342K | 3.7M |
| 2024-11-07 | Kjellson Nina S | Director | Sell | 2K | $17.32 | $41K | 449K |
| 2024-11-06 | Kjellson Nina S | Director | Sell | 6K | $17.18 | $97K | 452K |
| 2024-11-06 | Kjellson Nina S | Director | Sell | 47K | $17.18 | $805K | 3.8M |
| 2024-11-05 | Kjellson Nina S | Director | Sell | 1K | $16.77 | $19K | 457K |
| 2024-11-05 | Kjellson Nina S | Director | Sell | 9K | $16.77 | $157K | 3.8M |
| 2024-11-04 | Kjellson Nina S | Director | Sell | 116 | $17.01 | $2K | 458K |
| 2024-11-04 | Kjellson Nina S | Director | Sell | 960 | $17.01 | $16K | 3.8M |
| 2024-11-01 | Kjellson Nina S | Director | Sell | 604 | $17.16 | $10K | 3.8M |
| 2024-11-01 | Kjellson Nina S | Director | Sell | 3K | $16.54 | $48K | 459K |
| 2024-11-01 | Kjellson Nina S | Director | Sell | 24K | $16.54 | $396K | 3.8M |
| 2024-11-01 | Kjellson Nina S | Director | Sell | 73 | $17.16 | $1K | 459K |
| 2024-10-31 | Kjellson Nina S | Director | Sell | 89K | $16.46 | $1.5M | 3.8M |
| 2024-10-31 | Kjellson Nina S | Director | Sell | 11K | $16.46 | $177K | 461K |
| 2024-10-30 | Fuhrman Alan | Chief Financial Officer | Buy | 10K | $16.00 | $152K | 13K |
| 2024-10-30 | Kjellson Nina S | Director | Sell | 10K | $16.17 | $160K | 3.9M |
| 2024-10-30 | Kjellson Nina S | Director | Sell | 1K | $16.17 | $19K | 472K |
| 2024-10-21 | Harris Todd | President and CEO | Sell | 6K | $27.32 | $161K | 1.4M |
| 2024-10-21 | Harris Todd | President and CEO | Sell | 13K | $28.16 | $371K | 1.4M |
| 2024-10-18 | Kolchinsky Peter | Director,TenPercentOwner | Other transaction | 1.0M | price not stated in the filing | not stated | 7.5M |
| 2024-10-18 | Harris Todd | President and CEO | Sell | 44K | $27.01 | $1.2M | 1.4M |
| 2024-10-18 | Boxer Capital Management, LLC | Other | Returned to company | 2.0M | price not stated in the filing | not stated | 4.4M |
| 2024-10-17 | Harris Todd | President and CEO | Sell | 200 | $26.37 | $5K | 1.4M |
| 2024-10-17 | Harris Todd | President and CEO | Sell | 15K | $25.84 | $393K | 1.4M |
| 2024-10-16 | Harris Todd | President and CEO | Sell | 24K | $26.23 | $642K | 1.4M |
| 2024-10-16 | Harris Todd | President and CEO | Sell | 5K | $25.22 | $124K | 1.5M |
| 2024-10-16 | Harris Todd | President and CEO | Sell | 4K | $26.98 | $106K | 1.4M |
| 2024-10-15 | Harris Todd | President and CEO | Sell | 10K | $24.31 | $244K | 1.5M |
| 2024-09-30 | Harris Todd | President and CEO | Sell | 500 | $24.00 | $12K | 1.5M |
| 2024-09-25 | Harris Todd | President and CEO | Sell | 600 | $24.01 | $14K | 1.5M |
| 2024-09-24 | Harris Todd | President and CEO | Sell | 1K | $24.02 | $25K | 1.5M |
| 2024-09-23 | Harris Todd | President and CEO | Sell | 10K | $24.13 | $244K | 1.5M |
| 2024-09-20 | Harris Todd | President and CEO | Sell | 7K | $24.19 | $172K | 1.5M |
| 2024-09-19 | Harris Todd | President and CEO | Sell | 6K | $24.30 | $138K | 1.5M |
| 2024-09-19 | Harris Todd | President and CEO | Sell | 27 | $25.10 | $678 | 1.5M |
| 2024-09-18 | Harris Todd | President and CEO | Sell | 4K | $24.00 | $84K | 1.5M |
| 2024-09-13 | Fuhrman Alan | Chief Financial Officer | Grant | 954 | $12.48 | $12K | 3K |
| 2024-09-13 | Harris Todd | President and CEO | Grant | 1K | $6.58 | $9K | 1.5M |
| 2024-06-13 | KAPLAN GILLA | Director | Exercise or conversion | 61K | $0.61 | $37K | 90K |
| 2024-06-10 | Bensen Daniel | Chief Operating Officer | Sell | 4K | $20.00 | $70K | 428K |
| 2024-06-07 | Bensen Daniel | Chief Operating Officer | Sell | 200 | $20.00 | $4K | 431K |
| 2024-03-15 | Harris Todd | President and CEO | Grant | 2K | $6.58 | $12K | 1.5M |
| 2024-03-15 | Tada Hiroomi | Chief Medical Officer | Grant | 2K | $6.58 | $13K | 86K |
| 2024-03-15 | Fuhrman Alan | Chief Financial Officer | Grant | 932 | $12.48 | $12K | 2K |
| 2024-03-11 | Bensen Daniel | Chief Operating Officer | Sell | 200 | $20.00 | $4K | 432K |
| 2024-03-07 | Bensen Daniel | Chief Operating Officer | Sell | 68 | $20.00 | $1K | 432K |
| 2024-03-06 | Bensen Daniel | Chief Operating Officer | Sell | 2K | $20.09 | $35K | 432K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON10 Form 144 notices on file for TYRA worth $11.0M at the prices reported; 0 in the last 90 days worth $0. Latest: GILLA KAPLAN filed on 2026-03-25 to sell 14,295 shares ($529K) from 2026-03-25.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-03-25 | GILLA KAPLANDirector | 14K | $529K | 0.027% | 2026-03-25 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-12 | Daniel BensenOfficer | 8K | $283K | 0.015% | 2026-03-12 | Merrill Lynch |
| 2026-02-12 | Daniel BensenOfficer | 8K | $262K | 0.015% | 2026-02-12 | Merrill Lynch |
| 2026-01-12 | Daniel BensenOfficer | 8K | $232K | 0.015% | 2026-01-12 | Merrill Lynch |
| 2025-12-12 | Daniel BensenOfficer | 8K | $180K | 0.015% | 2025-12-12 | Merrill Lynch |
| 2025-11-21 | Alta Partners NextGen Fund II, L.P.Affiliate | 257K | $5.4M | 0.481% | 2025-11-21 | Merrill Lynch |
| 2025-11-18 | Daniel BensenOfficer | 125K | $2.0M | 0.233% | 2025-11-18 | Merrill Lynch |
| 2025-11-17 | Daniel BensenOfficer | 20K | $320K | 0.038% | 2025-11-17 | Merrill Lynch |
| 2025-11-14 | Daniel BensenOfficer | 86K | $1.4M | 0.162% | 2025-11-14 | Merrill Lynch |
| 2025-11-13 | Daniel BensenOfficer | 25K | $400K | 0.047% | 2025-11-13 | Merrill Lynch |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first, 50 of 67 shown. JSON20 holders report 5% or more of TYRA in their latest filing, 4 on Schedule 13D (active intent). The largest reported stake is Rajeev Shah at 19.9% of the class (14,130,492 shares), filed 2026-09-17 for an event on 2026-09-15.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-10-27 | 13G/Ano. 1 | BlackRock, Inc.parent holding company | 3.3M | 4.8% | 2026-09-30 |
| 2026-09-21 | 13G | BVF PARTNERS L P/ILinvestment adviser, partnership | 4.2M | 6.1% | 2026-09-14 |
| 2026-09-21 | 13G | BVF INC/ILcorporation | 4.2M | 6.1% | 2026-09-14 |
| 2026-09-21 | 13G | LAMPERT MARK Nindividual | 4.2M | 6.1% | 2026-09-14 |
| 2026-09-21 | 13G | BVF GP HOLDINGS LLCother entity | 3.9M | 5.6% | 2026-09-14 |
| 2026-09-21 | 13G | BVF I GP LLCother entity | 2.2M | 3.2% | 2026-09-14 |
| 2026-09-21 | 13G | BIOTECHNOLOGY VALUE FUND L Ppartnership | 2.2M | 3.2% | 2026-09-14 |
| 2026-09-21 | 13G | BVF II GP LLCother entity | 1.7M | 2.4% | 2026-09-14 |
| 2026-09-21 | 13G | BIOTECHNOLOGY VALUE FUND II LPpartnership | 1.7M | 2.4% | 2026-09-14 |
| 2026-09-21 | 13G | BVF Partners OS Ltd.corporation | 278K | 0.4% | 2026-09-14 |
| 2026-09-21 | 13G | Biotechnology Value Trading Fund OS LPpartnership | 278K | 0.4% | 2026-09-14 |
| 2026-09-17 | 13D/Ano. 7 | Rajeev Shahparent holding company, individual | 14.1M | 19.9% | 2026-09-15 |
| 2026-09-17 | 13D/Ano. 7 | Peter Kolchinskyparent holding company, individual | 14.1M | 19.9% | 2026-09-15 |
| 2026-09-17 | 13D/Ano. 7 | RA Capital Management, L.P.investment adviser, partnership | 14.1M | 19.9% | 2026-09-15 |
| 2026-09-17 | 13D/Ano. 7 | RA Capital Healthcare Fund, L.P.partnership | 12.1M | 17.2% | 2026-09-15 |
| 2026-09-17 | 13G | Paradigm BioCapital Advisors GP LLCother entity | 3.5M | 5.8% | 2026-09-10 |
| 2026-09-17 | 13G | Senai Asefaw, M.D.individual | 3.5M | 5.8% | 2026-09-10 |
| 2026-09-17 | 13G | Paradigm BioCapital Advisors LPpartnership | 3.5M | 5.8% | 2026-09-10 |
| 2026-09-17 | 13G | Paradigm BioCapital International Fund Ltd.corporation | 3.1M | 5.1% | 2026-09-10 |
| 2026-08-14 | 13G/Ano. 2 | Ian Charoubindividual | 3.6M | 6.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Nextech VI GP S.a. r.l.other entity | 3.6M | 6.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Nextech VI Oncology SCSppartnership | 3.6M | 6.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Rocco Sgobboindividual | 3.6M | 6.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Costas Constantinidesindividual | 3.6M | 6.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Roberts, Jr., Thomas G.parent holding company, individual | 6K | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Saito Edric C.parent holding company, individual | 6K | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Spokes, Andrew J. M.parent holding company, individual | 6K | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Warren, John R.parent holding company, individual | 6K | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Wehrly, Mark C.parent holding company, individual | 6K | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Short Daniel S.parent holding company, individual | 6K | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Farallon Capital Management, L.L.C.investment adviser, other entity | 6K | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Farallon Capital Partners, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Farallon Capital Institutional Partners, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Farallon Capital Institutional Partners II, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Farallon Capital Institutional Partners III, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Four Crossings Institutional Partners V, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Farallon Capital Offshore Investors II, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Farallon Capital (AM) Investors, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Farallon Capital F5 Master I, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Farallon Healthcare Partners Master, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Farallon Partners, L.L.C.other entity | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Farallon Institutional (GP) V, L.L.C.other entity | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Farallon F5 (GP), L.L.C.other entity | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Farallon Healthcare Partners (GP), L.L.C.other entity | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Dapice Joshua J.parent holding company, individual | 6K | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Dreyfuss, Philip D.parent holding company, individual | 6K | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Dunn Hannah E.parent holding company, individual | 6K | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Gehani, Varun N.parent holding company, individual | 6K | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Giauque, Nicolasparent holding company, individual | 6K | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Husen, Avner A.parent holding company, individual | 6K | 0.0% | 2026-06-30 |
13F holders
Tracked managers holding TYRA at their latest 13F. JSON6 of the 30 tracked managers held TYRA at their latest 13F, $32.5M in total at quarter-end prices. Two Sigma Investments is the largest at $14.4M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 5 added shares and 1 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Two Sigma Investments | 2026-06-30 | 450K | $14.4M | 0.01% | +348K |
| Citadel Advisors | 2026-06-30 | 278K | $8.9M | 0.00% | +263K |
| Millennium Management | 2026-06-30 | 178K | $5.7M | 0.00% | -44K |
| Fisher Asset Management | 2026-06-30 | 60K | $1.9M | 0.00% | +31K |
| AQR Capital Management | 2026-06-30 | 30K | $954K | 0.00% | +430 |
| D. E. Shaw & Co. | 2026-06-30 | 20K | $645K | 0.00% | new |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Tyra Biosciences in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Tyra Biosciences (TYRA), SEC CIK 1863127, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-25.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-03-25.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-10-27.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-04.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-09-15.JSON and CSV
- Company record
- EDGAR filing index for CIK 1863127Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of TYRA is sold short?
9,495,754 shares were held short at the 2026-10-15 settlement, 15.3 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is TYRA's daily short volume?
On 2026-11-02, 164,511 of the 202,778 TYRA shares reported to FINRA were sold short, 81.1% of the day's reported volume. Short volume is a flow for one day, not a position.
Does TYRA have fails to deliver?
The SEC's latest file shows 2,652 TYRA shares failed to deliver at settlement 2026-09-25. Fails are reported per settlement date and published twice a month with a lag.
Are TYRA insiders buying or selling?
Insiders at TYRA reported 1 open-market buy worth $20K in the last 90 days and no open-market sells. Latest filing: Fuhrman Alan (Chief Financial Officer) on 2026-09-15.
Have TYRA insiders filed to sell?
10 Form 144 notices on file for TYRA worth $11.0M at the prices reported; 0 in the last 90 days worth $0. Latest: GILLA KAPLAN filed on 2026-03-25 to sell 14,295 shares ($529K) from 2026-03-25.
Who owns 5% or more of TYRA?
20 holders report 5% or more of TYRA in their latest filing, 4 on Schedule 13D (active intent). The largest reported stake is Rajeev Shah at 19.9% of the class (14,130,492 shares), filed 2026-09-17 for an event on 2026-09-15.
Which tracked 13F managers own TYRA?
6 of the 30 tracked 13F managers held TYRA shares at their latest filing, $32.5M in all. The largest: Two Sigma Investments (450K shares, $14.4M), Ken Griffin's Citadel Advisors (278K shares, $8.9M), Izzy Englander's Millennium Management (178K shares, $5.7M), Ken Fisher's Fisher Asset Management (60K shares, $1.9M), Cliff Asness's AQR Capital Management (30K shares, $954K), D. E. Shaw & Co. (20K shares, $645K).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.